Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 13, 2021PLoS ONEOpen Access

The real-world outcomes of multiple myeloma patients treated with daratumumab

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAgoston Gyula SzaboUniversity of CopenhagenTKTobias Wirenfeldt KlausenCopenhagen University HospitalMLMette Bøegh LevringUniversity of Southern Denmark

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Szabo et al. (2021) studied this question.

synapsesocial.com/papers/6a180eb140149b897cb496cchttps://doi.org/10.1371/journal.pone.0258487
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma2016 · 1,457 citations
  2. 2Socioeconomic status is independently associated with overall survival in patients with multiple myeloma2015 · 73 citations
  3. 3Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 12011 · 1,047 citations
  4. 4Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma2016 · 1,534 citations
  5. 5Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity2016 · 63 citations